AbbVie CEO Gonzalez secured $21.6M in year marked by megamerger, Humira decline

gonzalez
Gonzalez secured $21.6 billion in total pay in 2019, slightly higher than the year before. (AbbVie)

AbbVie had a busy year in 2019 as it looked to close a $63 billion merger with Allergan while dealing with a sales decline for megablockbuster Humira abroad. Despite his wheeling and dealing––and the potential for a bright future ahead––that busy year didn't translate to a big pay bump for CEO Rick Gonzalez. 

Gonzalez, AbbVie's helmsman since its launch in 2013, netted $21.61 million in total pay in 2019, a modest increase from the $21.28 million he secured in 2018, according to a proxy filing

Gonzalez's base salary remained steady at $1.65 million with $8.89 million and $2.25 million stock and option awards, respectively––both decreases from the previous year. Gonzalez's pay came out higher primarily due to a nearly $3 million increase in pension value, which AbbVie tied to a change in "actuarial assumptions" and benefit accrual. 

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

Despite the small bump in pay, AbbVie said Gonzalez hit the company's internal marks for the year, including driving long-term business goals, advancing mid- and late-stage pipeline assets, driving employee engagement and helping AbbVie "advance our transformation to a biopharmaceutical culture."

RELATED: AbbVie, Allergan merger may face regulatory delay due to COVID-19 despite drug sell-off: report

Ranking at No. 7 on FiercePharma's list of the top 20 highest paid execs in biopharma in 2018, Gonzalez oversaw a hectic 12 months at AbbVie that included arranging the pending merger with Allergan, shepherding two potential blockbusters––psoriasis med Skyrizi and rheumatoid arthritis drug Rinvoq––to market, and handling the sales decline of Humira abroad.

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.